Senti Biosciences Holdings (SNTI) Assets Average (2021 - 2025)
Senti Biosciences Holdings (SNTI) posted quarterly Assets Average of $52.0 million for Q4 2025, down 33.2% year-over-year from $77.8 million in Q4 2024, and down 14.29% quarter-over-quarter from $60.6 million in Q3 2025.
Senti Biosciences Holdings (SNTI) Assets Average (2021 - 2025) Analysis & Trends
Senti Biosciences Holdings' Assets Average history runs 5 years deep, the most recent figure standing at $52.0 million for Q4 2025.
- In Q4 2025, Assets Average fell 33.2% year-over-year to $52.0 million; the TTM figure through Dec 2025 stood at $52.0 million (down 33.2% YoY), while the FY2025 annual figure was $74.5 million, down 31.41% from the prior year.
- Assets Average for Q4 2025 stood at $52.0 million, down from $60.6 million in the prior quarter.
- The five-year high for Assets Average was $231.8 million in Q3 2021, with the low at $52.0 million in Q4 2025.
- The 5-year median for Assets Average is $125.6 million (2023), against an average of $131.3 million.
- The sharpest annual moves came in 2022 and 2024: Assets Average soared 86.55% in 2022, then plunged 47.48% in 2024.
- Senti Biosciences Holdings' Assets Average stood at $164.2 million in 2021, then grew by 12.75% to $185.1 million in 2022, then plunged by 32.14% to $125.6 million in 2023, then plunged by 38.08% to $77.8 million in 2024, then plunged by 33.2% to $52.0 million in 2025.
- Business Quant data shows SNTI's Assets Average at $52.0 million in Q4 2025, $60.6 million in Q3 2025, and $75.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.81 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.52 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 65.30 Bn | 60.11 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.18 Bn | 54.04 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.77 Bn | 28.46 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.16 Bn | 26.32 Bn | - | 19.82 Bn |
| 10 | Senti Biosciences Holdings | 12.61 Mn | 12.61 Mn | - | 42.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 51.95 Mn |
| Sep 30, 2025 | 60.61 Mn |
| Jun 30, 2025 | 75.66 Mn |
| Mar 31, 2025 | 90.31 Mn |
| Dec 31, 2024 | 77.78 Mn |
| Sep 30, 2024 | 72.32 Mn |
| Jun 30, 2024 | 94.55 Mn |
| Mar 31, 2024 | 110.83 Mn |
| Dec 31, 2023 | 125.63 Mn |
| Sep 30, 2023 | 137.70 Mn |
| Jun 30, 2023 | 152.53 Mn |
| Mar 31, 2023 | 171.11 Mn |
| Dec 31, 2022 | 185.12 Mn |
| Sep 30, 2022 | 195.90 Mn |
| Jun 30, 2022 | 216.64 Mn |
| Mar 31, 2022 | 163.81 Mn |
| Dec 31, 2021 | 164.18 Mn |
| Sep 30, 2021 | 231.77 Mn |
| Jun 30, 2021 | 116.13 Mn |